Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Pharmaceuticals ETF (NY:XPH)

56.60 -0.08 (-0.14%)
Streaming Delayed Price Updated: 1:07 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 70,630
Open 56.43
Bid (Size) 56.60 (100)
Ask (Size) 56.67 (800)
Prev. Close 56.68
Today's Range 56.43 - 57.10
52wk Range 35.22 - 57.58
Shares Outstanding 36,002
Dividend Yield 0.80%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Did CRMD Stock Crash 28% Today? ↗
CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data. 
Via Stocktwits
News headline image
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them." 
Via Benzinga

Performance

YTD
+2.5%
+2.5%
1 Month
+0.2%
+0.2%
3 Month
+16.9%
+16.9%
6 Month
+33.6%
+33.6%
1 Year
+32.1%
+32.1%

More News

Read More
News headline image
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
Via Benzinga
Topics ETFs
News headline image
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗
Via Benzinga
Topics Government World Trade
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗
Via Benzinga
News headline image
Drug Tariffs Finally Land. Why Pharma Stocks Are Breathing Easy. ↗
Via Investor's Business Daily
Topics ETFs Government Intellectual Property
News headline image
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗
Via Benzinga
News headline image
Novo Nordisk Shares Plunge Amid Leadership Shakeup (NYSE:NVO)
Via MarketMinute
Topics ETFs Economy
News headline image
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗
Via Benzinga
Topics Government World Trade
News headline image
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗
Via Benzinga
Topics Government World Trade
News headline image
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗
Via Benzinga
News headline image
Trump Sparks New Chapter In Transatlantic Trade War: What The US Buys From Europe ↗
Via Benzinga
Topics Government World Trade
News headline image
Here's How Trump Plans To Tackle Drug Prices, And Why It Might Not Work ↗
Via Investor's Business Daily
Topics ETFs Government
News headline image
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion ↗
Via Benzinga
Topics Government
News headline image
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗
Via Benzinga
Topics ETFs Government
News headline image
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗
Via Stocktwits
Topics Government Intellectual Property Lawsuit
News headline image
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot ↗
Via Benzinga
Topics ETFs
News headline image
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗
Via Benzinga
Topics Government World Trade
News headline image
Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On? ↗
Via Benzinga
Topics World Trade
News headline image
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In ↗
Via Stocktwits
News headline image
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 ↗
Via Stocktwits
News headline image
Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027 ↗
Via Benzinga
News headline image
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors ↗
Via Benzinga
News headline image
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish ↗
Via Stocktwits

Frequently Asked Questions

Is State Street SPDR S&P Pharmaceuticals ETF publicly traded?
Yes, State Street SPDR S&P Pharmaceuticals ETF is publicly traded.
What exchange does State Street SPDR S&P Pharmaceuticals ETF trade on?
State Street SPDR S&P Pharmaceuticals ETF trades on the New York Stock Exchange
What is the ticker symbol for State Street SPDR S&P Pharmaceuticals ETF?
The ticker symbol for State Street SPDR S&P Pharmaceuticals ETF is XPH on the New York Stock Exchange
What is the current price of State Street SPDR S&P Pharmaceuticals ETF?
The current price of State Street SPDR S&P Pharmaceuticals ETF is 56.60
When was State Street SPDR S&P Pharmaceuticals ETF last traded?
The last trade of State Street SPDR S&P Pharmaceuticals ETF was at 01/08/26 01:07 PM ET
What is the market capitalization of State Street SPDR S&P Pharmaceuticals ETF?
The market capitalization of State Street SPDR S&P Pharmaceuticals ETF is 2.04M
How many shares of State Street SPDR S&P Pharmaceuticals ETF are outstanding?
State Street SPDR S&P Pharmaceuticals ETF has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.